RON HOOGEVEEN to Lipoproteins
This is a "connection" page, showing publications RON HOOGEVEEN has written about Lipoproteins.
Connection Strength
1.969
-
Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation. Clin Chem. 2021 01 08; 67(1):143-153.
Score: 0.677
-
Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease. J Am Coll Cardiol. 2018 07 10; 72(2):156-169.
Score: 0.569
-
Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study. Eur J Prev Cardiol. 2022 03 11; 29(2):e53-e64.
Score: 0.184
-
Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients. Transplantation. 2001 Oct 15; 72(7):1244-50.
Score: 0.179
-
Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. Atherosclerosis. 2014 Jan; 232(1):86-93.
Score: 0.103
-
Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study. Eur J Prev Cardiol. 2014 Jul; 21(7):866-75.
Score: 0.096
-
Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) carotid MRI study. Atherosclerosis. 2011 Dec; 219(2):596-602.
Score: 0.088
-
Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res. 2002 Aug; 43(8):1170-80.
Score: 0.047
-
The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT). Atherosclerosis. 2013 Dec; 231(2):371-7.
Score: 0.026